Compare UVSP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | EVO |
|---|---|---|
| Founded | 1876 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1994 | N/A |
| Metric | UVSP | EVO |
|---|---|---|
| Price | $44.21 | $1.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.67 | $7.00 |
| AVG Volume (30 Days) | ★ 247.9K | 44.2K |
| Earning Date | 04-22-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 21.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $328,056,000.00 | N/A |
| Revenue This Year | $11.65 | $1.37 |
| Revenue Next Year | $4.77 | $10.05 |
| P/E Ratio | $46.02 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $27.91 | $1.94 |
| 52 Week High | $45.46 | $4.42 |
| Indicator | UVSP | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 25.35 |
| Support Level | $42.91 | N/A |
| Resistance Level | $45.41 | $3.36 |
| Average True Range (ATR) | 0.85 | 0.10 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 70.35 | 1.02 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.